CyDex Pharmaceuticals Inc., a Lenexa, Kansas-based developer of drugs that “address limitations of current therapies in selected established,” has withdrawn registration of its $50 million IPO. It had planned to trade on the Nasdaq, with Pacific Growth Equities serving as lead underwriter.
CyDex has raised over $29 million in VC funding since 2000, from firms like TVM Capital, RiverVest Venture Partners, Life Sciences Opportunities Funds, S.R. One Ltd. and Eastman Chemical Company Investments. www.cydexinc.com